☰

Quanterix

Updating the operating model

Industry
Biotechnology
Public information as of
January 2026

A4BEE prepared this analysis from publicly available sources. It reflects our own reading of Quanterix's published strategy and is not endorsed by, or produced in cooperation with, Quanterix. Company website

Strategic priorities

Quanterix operates across 4 stated priorities, with the most concrete near-term plan anchored on grow assay menu.

Expanding the portfolio of ultra-sensitive biomarker assays beyond neurology into oncology and immunology applications, use 1,000-fold sensitivity advantage over traditional immunoassays.

Integrating Akoya Biosciences spatial biology capabilities to expand serviceable addressable market from $1 billion to $5 billion across the tissue-to-blood biomarker continuum.

Commercializing LucentAD Complete multi-marker blood test for Alzheimer's disease through CLIA-certified Accelerator Laboratory with 50-state clinical laboratory permits.

Challenges we see

  • Operations Manufacturing

    Multi-Site Manufacturing Consolidation

    Quanterix is consolidating four legacy manufacturing and lab facilities into two core sites (Billerica and Burlington), requiring merger of disparate SOPs, workforce cultures, and production workflows.

    CEO characterized site consolidation as "probably some of the most challenging parts of the integration," with increased risk of human error during production ramp-up and potential integration cost overruns.

  • Digital Integration

    Enterprise ERP Modernization

    The company is operating on a legacy ERP system while targeting a three-year transformative ERP work with hybrid integration of Salesforce, LIMS, QMS, and PLM disconnected instances into a single unified platform.

    Maintaining operational excellence while performing "lift and shift" to a new cloud-based ERP poses significant risks to productivity and financial reporting integrity during transition.

  • Digital Integration

    Instrument Data Interoperability

    Current instrument fleet (HD-X, SR-X, PhenoImager HT 2.0) utilizes diverse protocols and data schemas, creating data islands where tissue-based spatial insights cannot be cross-referenced with blood-based biomarker trends.

    Transition from proprietary hardware to third-party flow cytometer compatibility (20,000+ instruments) raises the risk of broken data chains and software integration failure.

  • Compliance Regulatory

    Financial Controls Material Weakness

    December 2024 financial restatements identified material weaknesses in internal controls over inventory valuation and property accounting, requiring improved data governance and automated financial monitoring.

    Unremediated material weaknesses could result in additional audit failures, regulatory scrutiny, and a slower path to profitability targets.

  • Compliance Regulatory

    Clinical Diagnostic GxP Compliance

    LucentAD commercialization requires adherence to stringent CLIA and FDA guideline performance standards with 90% sensitivity, specificity, and accuracy requirements for p-Tau 217 assays.

    Manual data entry in GxP environments and early-stage paperless processing pose significant audit risks, particularly with addition of Akoya spatial workflows.

Opportunities, by urgency and business impact

Each bubble is one opportunity, numbered to match the list below. Further right means it bites sooner; higher means a bigger effect on the business. A bigger bubble means a bigger implementation effort.

Source: A4BEE analysis of public sources

  1. Fragmented Manufacturing Data Systems

    Legacy equipment across consolidated sites is not fully connected to a central data lake, with manual data collection leading to 65% inefficiency in lab operations and lack of real-time visibility into production metrics.

    Implement Industrial Data Platform with IT/OT convergence to enable automatic data pipelines connecting physical manufacturing assets directly to ERP, providing unified operational visibility across Billerica and Burlington facilities.

  2. Inventory Control Data Integrity

    Material weaknesses in inventory valuation caused by failure in manual data chain between warehouse and finance department, creating audit risk and financial reporting inaccuracies without automated checks and balances.

    Deploy ontology-based Industrial Data Platform with automatic data pipelines to provide unparalleled sensitivity and qualitative clarity in financial reporting, eliminating manual transcription errors and ensuring real-time inventory accuracy.

  3. Simoa One Platform Interoperability

    Democratizing Simoa detection across 20,000+ third-party flow cytometers requires breakthrough in software interoperability between Quanterix digital detection algorithms and diverse flow cytometry data formats.

    use MTP (Module Type Package) and OPC UA standards to build Plug & Produce modularity into Simoa One kits, enabling smooth integration with third-party instruments through vendor-agnostic connectivity frameworks.

  4. Clinical Lab Paperless Processing

    Accelerator Laboratory and Lucent Diagnostics portal handle sensitive patient data with early-stage paperless processing, requiring enhanced GxP compliance and cybersecurity resilience for clinical diagnostic operations.

    Implement Zero Trust security architecture and GAMP5-compliant paperless lab solutions to ensure clinical patient data is handled securely while eliminating manual data entry risks in regulated environments.

  5. R&D Process Optimization Costs

    R&D costs approach 30% of revenue, with high-plex spatial assay development requiring expensive wet-lab experimentation to optimize process outcomes without predictive modeling capabilities.

    Implement Digital Twin simulations for biological processes to enable predictive modeling that identifies optimal process conditions, reducing failed experiments and accelerating assay development timelines from 18 months to under 6 months.

What we'd propose

  • Enterprise AI

    Industrial Data Platform for Manufacturing Excellence

    Ontology-based data platform with automatic pipelines connecting manufacturing floor assets (OT) directly to enterprise ERP (IT), resolving material weakness in inventory valuation and enabling real-time operational visibility.

    • Ontology layer

      A shared semantic model so lab, process, and quality data describe the same things the same way.

      DETAIL

    • Predictive models

      Models trained on the historical data plane that flag deviations before they become scrap.

      DETAIL

    • Decision surfaces

      Single pane of glass that surfaces model output to the right role at the right moment.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Enterprise AI
  • Digital Lab

    Digital Lab Integration for Site Consolidation

    Comprehensive IT/OT convergence solution to integrate diverse laboratory equipment across Billerica and Burlington sites into unified digital platform, reducing data collection time by 65% and enabling remote monitoring.

    • Unified data backbone

      Connect instruments and LIMS into a single data spine so QC and CDMO records are queryable across sites.

      DETAIL

    • Paperless workflows

      Move lab execution from paper to instrument-captured records with full audit trail.

      DETAIL

    • Continuous QC release

      Review-by-exception dashboards that flag only the records needing scientist attention.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Digital Lab
  • Digital CDMO

    MTP-Compliant Platform Interoperability Framework

    Module Type Package (MTP) and OPC UA connectivity framework enabling Simoa One kits to achieve Plug & Produce compatibility with 20,000+ third-party flow cytometers through vendor-agnostic standardization.

    • OT/IT convergence

      Pull sensor and controller data off the line into a shared data plane in real time.

      DETAIL

    • Batch intelligence

      Golden-batch comparison and deviation detection running on the same data plane.

      DETAIL

    • Production release flow

      Closed-loop between QA, MES, and ERP so batch record review and release follow the data, not the paperwork.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Digital CDMO
  • Digital Lab

    GxP Paperless Lab and Cybersecurity Framework

    GAMP5-compliant paperless laboratory solution with Zero Trust security architecture for Lucent Diagnostics clinical operations, ensuring 90% sensitivity standards while eliminating manual data entry risks.

    • Unified data backbone

      Connect instruments and LIMS into a single data spine so QC and CDMO records are queryable across sites.

      DETAIL

    • Paperless workflows

      Move lab execution from paper to instrument-captured records with full audit trail.

      DETAIL

    • Continuous QC release

      Review-by-exception dashboards that flag only the records needing scientist attention.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Digital Lab
  • Digital Lab

    Digital Twin for Bioprocess Simulation

    Cloud-agnostic platform for digital simulation of spatial and blood-based biomarker processes, enabling predictive modeling to optimize assay development and reduce R&D experimentation costs.

    • Unified data backbone

      Connect instruments and LIMS into a single data spine so QC and CDMO records are queryable across sites.

      DETAIL

    • Paperless workflows

      Move lab execution from paper to instrument-captured records with full audit trail.

      DETAIL

    • Continuous QC release

      Review-by-exception dashboards that flag only the records needing scientist attention.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Digital Lab

Digital maturity: today and target

Scored out of 100 across six dimensions. The target is what Quanterix's own published ambition implies — not a perfect score.

Source: A4BEE analysis of public sources
IT/OT Integration 35 → 80
Legacy equipment not connected to central data lake; material weakness in inventory controls indicates fragmented data pipelines; diverse instrument protocols creating data silos
Data Governance 30 → 85
Financial restatements indicate inadequate automated checks; manual data collection across manufacturing sites; lack of unified ontology for production data
Manufacturing Automation 45 → 85
A single manufacturing team manages consolidated sites; retrofitting the legacy equipment for real-time asset tracking is the opportunity.
Regulatory Compliance 50 → 90
CLIA certification in 50 states achieved; early-stage paperless processing; GxP compliance requires enhanced automation for 90% accuracy targets
Platform Interoperability 40 → 90
Simoa One requires compatibility with 20,000+ third-party instruments; diverse protocols between HD-X, SR-X, PhenoImager; MTP/OPC UA standardization needed
Cybersecurity Resilience 45 → 85
Clinical patient data processing requires Zero Trust architecture; multi-state laboratory operations increase attack surface; Akoya integration adds complexity

Check this yourself

Our Service Portal has free self-assessments and market comparisons. These are the ones that line up with what we've read above — no sales call required.

Think we've read this right?

Talk to us

Related reading

This is an independent analysis prepared by A4BEE from publicly available information as of January 2026. It reflects A4BEE's own interpretation and opinion, is not affiliated with, endorsed by, or verified with Quanterix, and may be incomplete or inaccurate. All company names and trademarks are the property of their respective owners. To request a correction or removal, contact [email protected].